To evaluate the long-term effect of latanoprost on central corneal thickness (CCT) in patients with normal-tension glaucoma (NTG).
Methods:
This retrospective study included 41 eyes of 41 NTG patients and 40 eyes of 40 individuals with glaucoma suspect (controls). Newly diagnosed NTG patients with no previous glaucoma treatment were administered latanoprost 0.005% monotherapy once a day. CCTs were measured by ultrasound pachymetry before treatment and followed up annually for 5 years.
Results:
A significant reduction in mean CCT was observed in the NTG group [542.3±36.2 μm vs. 533.7±32.9 μm (n=41), P<0.001], but not in the control group [547.4±24.7 μm vs. 546.8±25.0 μm (n=40), P=0.59] at 5-year follow-up. In the NTG group, the CCT reduction mainly occurred during the first year of treatment (542.3±36.2 μm vs. 536.9±32.8 μm, P=0.001), and no significant correlation was found between CCT and intraocular pressure reductions (r=0.16, P=0.32).
Conclusions:
Latanoprost significantly reduced CCT in NTG patients after 5 years of treatment. Serial observations of CCT might be helpful for the proper interpretation of glaucoma status in NTG patients.
Get full access to this article
View all access options for this article.
References
1.
MudumbaiR.C.Clinical update on normal tension glaucoma. Semin. Ophthalmol., 28:173–179, 2013.
2.
EhlersN., BramsenT., and SperlingS.Applanation tonometry and central corneal thickness. Acta Ophthalmol (Copenh.), 53:34–43, 1975.
3.
HerndonL.W., WeizerJ.S., and StinnettS.S.Central corneal thickness as a risk factor for advanced glaucoma damage. Arch. Ophthalmol., 122:17–21, 2004.
4.
KurtzS., HaberI., and KeslerA.Corneal thickness measurements in normal-tension glaucoma workups: is it worth the effort?. J. Glaucoma., 19:58–60, 2010.
5.
RussoA., RivaI., PizzolanteT., NotoF., and QuarantaL.Latanoprost ophthalmic solution in the treatment of open angle glaucoma or raised intraocular pressure: a review. Clin. Ophthalmol., 2:897–905, 2008.
6.
SchachtschabelU., LindseyJ.D., and WeinrebR.N.The mechanism of action of prostaglandins on uveoscleral outflow. Curr. Opin. Ophthalmol., 11:112–115, 2000.
7.
SagaraT., GatonD.D., LindseyJ.D., et al.Topical prostaglandin F2alpha treatment reduces collagen types I, III, and IV in the monkey uveoscleral outflow pathway. Arch. Ophthalmol., 117:794–801, 1999.
8.
BenEzraD., and FoidartJ.M.Collagens and non collagenous proteins in the human eye. I. Corneal stroma in vivo and keratocyte production in vitro. Curr. Eye Res., 1:101–110, 1981.
9.
KimH.J., and ChoB.J.Long-term effect of latanoprost on central corneal thickness in normal tension glaucoma. J. Ocul. Pharmacol. Ther., 27:73–76, 2011.
10.
YouJ.Y., and ChoB.J.Effect of latanoprost on central corneal thickness in unilateral normal-tension glaucoma. J. Ocul. Pharmacol. Ther., 29:335–338, 2013.
11.
ViswanathanD., GoldbergI., and GrahamS.L.Longitudinal effect of topical antiglaucoma medications on central corneal thickness. Clin. Experiment Ophthalmol., 41:348–354, 2013.
12.
OhD.J., MartinJ.L., WilliamsA.J., et al.Analysis of expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human ciliary body after latanoprost. Invest. Ophthalmol. Vis. Sci., 47:953–963, 2006.
13.
SivakJ.M., and FiniM.E.MMPs in the eye: emerging roles for matrix metalloproteinases in ocular physiology. Prog. Retin. Eye Res., 21:1–14, 2002.
14.
LindseyJ.D., KashiwagiK., KashiwagiF., and WeinrebR.N.Prostaglandins alter extracellular matrix adjacent to human ciliary muscle cells in vitro. Invest. Ophthalmol. Vis. Sci., 38:2214–2223, 1997.
15.
HondaN., MiyaiT., NejimaR., et al.Effect of latanoprost on the expression of matrix metalloproteinases and tissue inhibitor of metalloproteinase 1 on the ocular surface. Arch. Ophthalmol., 128:466–471, 2010.
16.
Lopilly ParkH.Y., KimJ.H., LeeK.M., and ParkC.K.Effect of prostaglandin analogues on tear proteomics and expression of cytokines and matrix metalloproteinases in the conjunctiva and cornea. Exp. Eye Res., 94:13–21, 2012.
17.
WuK.Y., WangH.Z., and HongS.J.Effect of latanoprost on cultured porcine corneal stromal cells. Curr. Eye Res., 30:871–879, 2005.
18.
MaruyamaY., MoriK., IkedaY., UenoM., and KinoshitaS.Effects of long-term topical prostaglandin therapy on central corneal thickness. J. Ocul. Pharmacol. Ther., 30:440–444, 2014.
19.
ZhongY., ShenX., YuJ., TanH., and ChengY.The comparison of the effects of latanoprost, travoprost, and bimatoprost on central corneal thickness. Cornea., 30:861–864, 2011.
20.
BrewK., DinakarpandianD., and NagaseH.Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim. Biophys. Acta., 1477:267–283, 2000.
21.
AnthonyT.L., LindseyJ.D., and WeinrebR.N.Latanoprost's effects on TIMP-1 and TIMP-2 expression in human ciliary muscle cells. Invest. Ophthalmol. Vis. Sci., 43:3705–3711, 2002.
22.
OhD.J., MartinJ.L., WilliamsA.J., et al.Effect of latanoprost on the expression of matrix metalloproteinases and their tissue inhibitors in human trabecular meshwork cells. Invest. Ophthalmol. Vis. Sci., 47:3887–3895, 2006.
23.
KunapuliP., LawsonJ.A., RokachJ., and FitzGeraldG.A.Functional characterization of the ocular prostaglandin f2alpha (PGF2alpha) receptor. Activation by the isoprostane, 12-iso-PGF2alpha. J. Biol. Chem., 272:27147–27154, 1997.
24.
FiniM.E., and StramerB.M.How the cornea heals: cornea-specific repair mechanisms affecting surgical outcomes. Cornea., 24:S2–S11, 2005.
25.
SchloteT., TzamalisA., and KynigopoulosM.Central corneal thickness during treatment with travoprost 0.004% in glaucoma patients. J. Ocul. Pharmacol. Ther., 25:459–462, 2009.
26.
PanosG.D., KonstantinidisA., MendrinosE., et al.Effect of tafluprost 0.0015% on central corneal thickness in patients with primary open-angle glaucoma. Curr. Eye Res., 38:977–982, 2013.
